Hotspot point mutations in IDH1/2 occur in the vast majority of adult low-grade gliomas (3) representing a potential therapeutic target since IDH mutation is an early oncogenetic event, stable overtime, whose molecular downstream pathway is well known. The gene discussed is IDH2; the disease is glioma.